Global Long-acting Injectable Antipsychotics (LAIs) Market Growth 2024-2030

Global Long-acting Injectable Antipsychotics (LAIs) Market Growth 2024-2030

Long-acting injectable (LAI) antipsychotics are unique medication formulations used in psychiatric pharmacy to help improve patient outcomes. They offer several benefits compared to oral therapy, including confirmed patient adherence, consistent drug delivery, predictable bioavailability, and prevention of antipsychotic overdose.

The global Long-acting Injectable Antipsychotics (LAIs) market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Long-acting Injectable Antipsychotics (LAIs) Industry Forecast” looks at past sales and reviews total world Long-acting Injectable Antipsychotics (LAIs) sales in 2023, providing a comprehensive analysis by region and market sector of projected Long-acting Injectable Antipsychotics (LAIs) sales for 2024 through 2030. With Long-acting Injectable Antipsychotics (LAIs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Injectable Antipsychotics (LAIs) industry.

This Insight Report provides a comprehensive analysis of the global Long-acting Injectable Antipsychotics (LAIs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Injectable Antipsychotics (LAIs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Injectable Antipsychotics (LAIs) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Injectable Antipsychotics (LAIs) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Injectable Antipsychotics (LAIs).

United States market for Long-acting Injectable Antipsychotics (LAIs) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Long-acting Injectable Antipsychotics (LAIs) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Long-acting Injectable Antipsychotics (LAIs) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Long-acting Injectable Antipsychotics (LAIs) players cover Otsuka Pharmaceutical, CHEPLAPHARM Arzneimittel GmbH, Alkermes Pharma Ireland Limited, Essential Pharma, Janssen Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Injectable Antipsychotics (LAIs) market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
First-generation
Second-generation

Segmentation by Application:
Schizophrenia
Bipolar Disorder
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Otsuka Pharmaceutical
CHEPLAPHARM Arzneimittel GmbH
Alkermes Pharma Ireland Limited
Essential Pharma
Janssen Pharmaceuticals
Indivior UK Limited
Qilu Pharmaceutical
Lvye Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Long-acting Injectable Antipsychotics (LAIs) market?

What factors are driving Long-acting Injectable Antipsychotics (LAIs) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Long-acting Injectable Antipsychotics (LAIs) market opportunities vary by end market size?

How does Long-acting Injectable Antipsychotics (LAIs) break out by Type, by Application?



Please note: The report will take approximately 2 business days to prepare and deliver.